---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-032403"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2026-03-20T23:59:59+00:00"
generated_at: "2026-05-15T09:29:13.916238+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Relmada FY2025 net loss $57.4M; NDV-01 76% CR at 12 months; $160M PIPE closed

## Summary
- FY2025 net loss $57.4M ($1.45/share) vs $80.0M in FY2024; Q4 net loss $19.9M ($0.27/share).
- NDV-01 Phase 2: 95% CR at any time, 76% durable CR at 12 months in high-risk NMIBC; BCG-unresponsive 80% CR at 12 months.
- Oversubscribed $160M PIPE closed March 2026; cash $93M at Dec 31, 2025 plus PIPE expected to fund operations through 2029.
- R&D expense $26.9M (down from $46.2M); G&A $32.2M (down from $37.7M); shares outstanding 104.9M.
- On track to start Phase 3 RESCUE program and Sepranolone Phase 2 in Prader-Willi mid-2026.

## SEC filing metadata
- accession: 0001213900-26-032403
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2026-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390026032403/0001213900-26-032403-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390026032403/ea0282688-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-032403
- JSON: https://secwatch.observer/filing/0001213900-26-032403.json
- Plain text: https://secwatch.observer/filing/0001213900-26-032403.txt

## Key facts
- Earnings Releases
  RELMADA THERAPEUTICS, INC. reported financial results for the fourth quarter and full year ended December 31, 2025.
  - Period: the fourth quarter and full year ended December 31, 2025
  - Result: reported results
  source text: Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1553643/000121390026032403/0001213900-26-032403-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.